You just read:

KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody

News provided by

KaloBios Pharmaceuticals, Inc.

Dec 10, 2013, 09:00 ET